Overview
Also known as:
Clinical phenotype terms— hover any for plain English:
FDA & Trial Timeline
4 eventsGrand Shuyang Life Sciences (Chengdu) Co., Ltd. — PHASE3
University of Minnesota — PHASE2
Fundación Española de Hematología y Hemoterapía
University of Cologne
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
3 availableCablivi
CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immun…
CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
Doptelet
treatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
Adzynma
prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
2 resourcesTravel Grants
No travel grants are currently matched to Immune-mediated thrombotic thrombocytopenic purpura.
Community
No community posts yet. Be the first to share your experience with Immune-mediated thrombotic thrombocytopenic purpura.
Start the conversation →Latest news about Immune-mediated thrombotic thrombocytopenic purpura
Disease timeline:
New recruiting trial: An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
New recruiting trial: Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
New recruiting trial: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
New recruiting trial: Short-course High-dose Prednisone and Dexamethasone in Children With ITP
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
New recruiting trial: Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
New recruiting trial: Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
A new clinical trial is recruiting patients for Immune-mediated thrombotic thrombocytopenic purpura
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Immune-mediated thrombotic thrombocytopenic purpura
Are there clinical trials for Immune-mediated thrombotic thrombocytopenic purpura?
Yes — 3 recruiting clinical trials are currently listed for Immune-mediated thrombotic thrombocytopenic purpura on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Immune-mediated thrombotic thrombocytopenic purpura?
25 specialists and care centers treating Immune-mediated thrombotic thrombocytopenic purpura are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Immune-mediated thrombotic thrombocytopenic purpura?
2 patient support programs are currently tracked on UniteRare for Immune-mediated thrombotic thrombocytopenic purpura. See the treatments and support programs sections for copay assistance, eligibility, and contact details.